About Kiyatec
Kiyatec is a company based in Pendleton (United States) founded in 2005 by Matt Gevaert. It operates as a HealthTech. Kiyatec has raised $29.49 million across 13 funding rounds from investors including LabCorp, Bruker and HHS. Kiyatec offers products and services including 3D Predict Platform, 3D Predict Tumor-Specific, 3D Predict Glioma, and KIYA-Predict. Kiyatec operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Pendleton, United States
- Founders Matt Gevaert
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kiyatec
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$29.49 M (USD)
in 13 rounds
-
Latest Funding Round
Not available
-
Investors
LabCorp
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kiyatec
Kiyatec offers a comprehensive portfolio of products and services, including 3D Predict Platform, 3D Predict Tumor-Specific, 3D Predict Glioma, and KIYA-Predict.
A platform for tumor-specific cancer treatment prediction.
Tumor-specific analysis for personalized cancer therapy solutions.
Specialized glioma analysis for targeted cancer treatment options.
Predictive tool for oncology treatment planning and decisions.
People of Kiyatec
Unlock access to complete
Funding Insights of Kiyatec
Kiyatec has successfully raised a total of $29.49M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kiyatec
Kiyatec has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Bruker and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Philanthropic capital is invested to advance brain tumor treatments.
|
Locked | Locked | Locked | |
|
Venture capital investments are made in healthcare and fintech sectors.
|
Locked | Locked | Locked | |
|
Early-stage ventures in the Southeast are supported by VentureSouth.
|
Locked | Locked | Locked |
Investor details for Kiyatec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kiyatec
Investment portfolio details for Kiyatec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kiyatec
Detailed financials for Kiyatec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kiyatec Comparisons
Peer comparison for Kiyatec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kiyatec
Kiyatec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Kiyatec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kiyatec
Complete news archive for Kiyatec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kiyatec
Kiyatec was founded in 2005 and raised its 1st funding round 4 years after it was founded.
Kiyatec is headquartered in Pendleton, United States. It is registered at Pendleton, Oregon, United States.
Kiyatec is a funded company, having raised a total of $29.49M across 13 funding rounds to date.
Kiyatec is engaged in developing advanced 3D predictive platforms for cancer care. The company operates within the healthcare and biotechnology sector, specializing in tumor-specific diagnostics and personalized treatment solutions. Platforms such as 3D Predict and KIYA-Predict are designed to assist oncologists, neuro-oncologists, and other healthcare professionals in making informed treatment decisions. Services are extended to patients and caregivers, aiming to improve outcomes in oncology, particularly for complex cases like glioma. The company is headquartered in Greenville, United States, and collaborates with drug development professionals and pharmaceutical researchers to advance cancer therapy solutions.
Kiyatec's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Kiyatec offers 3D Predict Platform, 3D Predict Tumor-Specific, 3D Predict Glioma, and KIYA-Predict.
Kiyatec has 11 investors. Key investors include LabCorp, Bruker, HHS, SCRA, and The Sontag Foundation.